Gastric outlet obstruction

(Redirected from GOO)
Jump to navigation Jump to search

Gastric outlet obstruction Microchapters

Home

Overview

Classification

Pathophysiology

Causes

Differentiating Gastric outlet obstruction from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Diagnosis

Treatment

Medical Therapy
Surgery

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Fahad Hasan, M.D.[2] Sudarshana Datta, MD [3]

Synonyms and keywords: GOO

Overview

Gastric outlet obstruction (GOO) is a clinical syndrome characterized by epigastric abdominal pain and postprandial vomiting due to mechanical obstruction. Also referred to as pyloric obstruction, it is not a single disease entity but rather the clinical and pathophysiological consequence of any process that produces a mechanical impediment to gastric emptying at the level of the distal stomach, pyloric channel, or duodenum. Infiltration, scar formation or inflammation of the gastric outlet leads to intrinsic obstruction, while malignancy of neighboring structures such as the pancreas, gallbladder, liver and duodenum may lead to extrinsic obstruction of the gastric outlet.

The epidemiology of GOO has shifted dramatically over the past five decades. Historically, peptic ulcer disease (PUD) accounted for up to 90 percent of cases until the late 1970s. With the advent of effective H2 blockers and proton pump inhibitors, along with H. pylori eradication strategies, peptic ulcer disease has declined significantly. Consequently, it is now estimated that 50 to 80 percent of all cases of GOO are attributable to malignancy.[1]

Common benign causes of GOO include peptic ulcer disease (PUD) (approximately 5% of PUD cases develop GOO), gastric polyps, caustic ingestion, duodenal stricture, systemic amyloidosis of the gastrointestinal tract, eosinophilic gastroenteritis, and obstruction by gallstones (Bouveret syndrome). Common malignant causes include pancreatic cancer (15–25% of pancreatic cancer patients develop GOO), gastric cancer (accounting for up to 35% of malignant GOO cases), ampullary cancer, and cholangiocarcinoma.

GOO presents with nausea, vomiting, dehydration, electrolyte abnormalities, weight loss, malnutrition, fullness of the epigastrium, early satiety, and bloating. Laboratory findings often reveal hypokalemic hypochloremic metabolic alkalosis, a characteristic feature resulting from gastric acid loss due to vomiting.

Diagnosis involves clinical assessment, laboratory studies, and imaging modalities including barium upper GI studies and computed tomography. Upper endoscopy is the primary diagnostic tool, allowing visualization of the gastric outlet, identification of the obstruction site, biopsy sampling for histologic evaluation, and exclusion of malignancy.

Management depends on the underlying etiology, patient performance status, and acuity of presentation. Initial management includes supportive care with nasogastric decompression, fluid resuscitation, and electrolyte correction. For benign obstruction due to PUD, medical therapy with proton pump inhibitors is typically first-line. Endoscopic management with balloon dilation, self-expandable metal stent (SEMS) placement, or endoscopic ultrasound-guided gastroenterostomy (EUS-GE) using lumen-apposing metal stents (LAMS) is effective for selected benign and malignant causes. The 2025 ENDURO randomized controlled trial demonstrated that EUS-GE is superior to surgical gastroenterostomy for time to resumption of solid oral intake and non-inferior for reintervention rates, establishing EUS-GE as the preferred palliative treatment for malignant GOO in appropriate candidates.[2] Surgery remains an important option, particularly for benign disease with chronic scarring and for fit patients with malignant obstruction amenable to resection.

Historical Perspective

Historically, GOO was predominantly a complication of peptic ulcer disease. Benign disease, primarily peptic ulceration, was responsible for the majority of GOO cases until the late 1970s, with peptic ulcer disease accounting for up to 90 percent of cases in older series. The introduction of H2-receptor antagonists in the 1970s and proton pump inhibitors (PPIs) in the 1980s markedly reduced the burden of complicated peptic ulcer disease, leading to a dramatic decline in benign GOO. Subsequently, the discovery and treatment of Helicobacter pylori infection further curtailed ulcer-related complications.

The epidemiologic landscape consequently shifted toward malignant causes, with pancreatic cancer emerging as the leading etiology in developed countries. Surgical gastrojejunostomy remained the cornerstone of palliation for malignant GOO for decades. The 1990s saw the introduction of endoscopic balloon dilation (EBD) for benign strictures and, later, the placement of self-expandable metal stents for malignant obstruction. The first decade of the 21st century brought comparative trials of SEMS versus surgical gastrojejunostomy (including the SUSTENT multicenter RCT). The most transformative recent development has been EUS-guided gastroenterostomy using LAMS, first described clinically in the early 2010s, which combines the durability of a surgical bypass with the minimally invasive nature of an endoscopic approach. The 2021 ASGE guideline established evidence-based recommendations for endoscopic management of GOO,[3] and the 2025 ENDURO RCT further elevated EUS-GE to the preferred palliative modality for eligible patients with malignant GOO.[2]

Classification

GOO is classified according to its etiology and the nature of the obstructing pathology:

By Etiology

Category Examples
Benign Peptic ulcer disease, caustic ingestion stricture, Crohn disease, hypertrophic pyloric stenosis, annular pancreas, pancreatitis (acute or chronic), pancreatic pseudocyst, Bouveret syndrome, eosinophilic gastroenteritis, gastric bezoar, gastric volvulus, inflammatory polyps, iatrogenic (anastomotic stricture, post-ESD/EMR)
Malignant Pancreatic adenocarcinoma, distal gastric cancer, cholangiocarcinoma, ampullary carcinoma, duodenal adenocarcinoma, lymphoma, gastrointestinal stromal tumor, metastatic disease

By Mechanism

Mechanism Description
Intrinsic obstruction Mucosal or mural pathology directly narrowing the gastric outlet or duodenum (e.g., ulcer scar, neoplastic infiltration)
Extrinsic compression External mass compressing the duodenum or pyloric region (e.g., pancreatic head tumor, pseudocyst)
Functional (pseudo-obstruction) Impaired gastric motility without mechanical obstruction (e.g., diabetic gastroparesis); must be excluded before treating as mechanical GOO

Pediatric Classification

In the pediatric population, GOO classification extends beyond hypertrophic pyloric stenosis to include congenital duodenal atresia, duodenal web, annular pancreas, and malrotation.[4]

Pathophysiology

The pathophysiological consequences of GOO stem from mechanical impedance to the passage of gastric contents into the duodenum and small intestine. As the obstruction progresses, intragastric pressure rises, provoking reflex vomiting. Early in the course, patients may tolerate liquids better than solids; over time, even liquids cannot pass, and the stomach progressively dilates. Sustained gastric distension eventually causes loss of contractility, with deposition of undigested food within the stomach.

Persistent vomiting has predictable metabolic consequences. Loss of hydrochloric acid and potassium from gastric secretions results in hypokalemic hypochloremic metabolic alkalosis, the hallmark biochemical derangement of prolonged GOO. The kidneys attempt to compensate by retaining hydrogen ions in exchange for potassium excretion, leading to paradoxical aciduria despite systemic alkalosis.

Nutritional consequences follow prolonged obstruction, with caloric deficit, protein-energy malnutrition, vitamin deficiencies, and progressive cachexia. These are particularly pronounced when a malignant etiology coexists and systemic tumor burden accelerates catabolism.

Benign obstructions (e.g., from peptic ulcer disease) typically arise from a combination of acute mucosal edema, inflammatory swelling, and chronic fibrotic scarring of the pylorus or duodenal bulb. In contrast, malignant GOO results from tumoral infiltration, extrinsic compression, or encasement of the gastroduodenal lumen. The reversibility of obstruction depends on the underlying cause: edematous benign strictures may resolve with medical therapy, whereas fibrotic or malignant obstructions typically require procedural or surgical intervention.[3]

Causes

Causes of GOO are classified as benign or malignant.

Benign Causes

Benign causes may be congenital or acquired. Acquired benign causes are further categorized as acute (resulting from edema and inflammation) or chronic (resulting from fibrosis and scar formation).

Benign Acquired Causes

Benign Congenital Causes

Malignant Causes

Malignancy now accounts for 50–80% of GOO cases in developed nations.[1] The most common primary malignancies causing GOO are:

Differentiating Gastric outlet obstruction from Other Diseases

The differential diagnosis of GOO includes both mechanical and functional conditions presenting with vomiting and impaired gastric emptying:

Condition Key Distinguishing Features
Gastroparesis No mechanical obstruction on endoscopy or imaging; delayed gastric emptying scintigraphy positive; associated with diabetes mellitus, post-vagotomy, or idiopathic causes; no structural narrowing of pylorus or duodenum
Peptic ulcer disease without GOO Ulcer identified on endoscopy without significant luminal narrowing; no succussion splash; pylorus patent on endoscopy
Gastric cancer without obstruction Mass lesion on endoscopy and imaging without luminal compromise sufficient to cause GOO; differentiated by cross-sectional imaging and endoscopic biopsy
Pancreatic cancer without GOO Peripancreatic mass on imaging without obstruction of gastric outlet; GOO may develop as disease progresses
Small bowel obstruction Obstruction distal to the duodenum; dilated small bowel loops on abdominal imaging; different clinical presentation
Cyclic vomiting syndrome Episodic, stereotyped vomiting without mechanical obstruction; often triggered by specific stimuli; no structural lesion
Superior mesenteric artery syndrome Compression of the third portion of the duodenum between the superior mesenteric artery and aorta; identified on CT angiography; associated with significant weight loss
Rumination syndrome Effortless regurgitation shortly after meals without nausea; no obstructive lesion; pressure manometry diagnostic
Intestinal pseudo-obstruction (Ogilvie syndrome) Colonic dilation without mechanical obstruction; distinguished by imaging

Epidemiology and Demographics

Precise population-based incidence data for GOO are limited, in part because GOO is a syndrome rather than a single disease. The following generalizations are supported by contemporary case series and registry data:

  • Malignant etiologies now account for approximately 50–80% of GOO cases in contemporary adult series in developed nations.[1]
  • Pancreatic adenocarcinoma is the most frequent individual malignant cause; 15–25% of patients with pancreatic cancer develop GOO at some point during the course of their illness.[1]
  • Distal gastric cancer accounts for up to 35% of malignant GOO in some series; its contribution has decreased in Western countries following declining rates of gastric cancer overall.
  • Among benign causes, peptic ulcer disease predominates in most world regions, though the absolute frequency has fallen dramatically since the widespread adoption of H2-receptor antagonists, PPIs, and Helicobacter pylori eradication therapy; GOO now occurs in fewer than 5% of patients with peptic ulcer disease.
  • In a single-center retrospective series of 76 hospitalized patients with GOO (2006–2015), 38% of cases were malignant and 62% were benign; among malignant causes, pancreatic adenocarcinoma accounted for 17%, gastric adenocarcinoma for 7%, and cholangiocarcinoma, ampullary cancer, duodenal adenocarcinoma, hepatocellular carcinoma, and metastatic disease for the remainder; among benign causes, peptic ulcer disease (17%) and postoperative strictures/adhesions (14%) were most common.[11]
  • GOO affects males more commonly than females, with a male-to-female ratio of approximately 3–4:1 across most series.
  • In the pediatric population, hypertrophic pyloric stenosis is the dominant etiology, occurring in approximately 1 per 750 births and with a 4:1 male predominance; it is the most common reason for abdominal surgery in infants during the first six months of life.
  • In developing nations, caustic ingestion and gastric tuberculosis remain relatively more common causes of benign GOO.

Risk Factors

Risk factors for GOO vary by underlying etiology:

Screening

There are no established population-level screening recommendations specifically for GOO. The following considerations apply in at-risk groups:

  • Patients with known periampullary or pancreatic malignancy should be monitored clinically for early symptoms of GOO (nausea, early satiety, postprandial vomiting, weight loss) at each oncologic visit.
  • Patients with long-standing, poorly controlled peptic ulcer disease or recurrent duodenal ulceration should undergo periodic assessment for the development of pyloric/duodenal stricture.
  • Prophylactic gastrojejunostomy at the time of surgical exploration for unresectable periampullary cancer remains an area of ongoing debate. One randomized trial demonstrated a 0% rate of subsequent GOO in those who received prophylactic gastrojejunostomy versus a higher rate in controls, with no significant difference in operative morbidity, hospital length of stay, or survival.[12]

Natural History, Complications and Prognosis

The natural history and prognosis of GOO depend upon the underlying etiology, duration of obstruction, and patient fitness for treatment.

Benign GOO

  • Natural History: Benign GOO often presents insidiously with progressive symptoms. Acute obstruction can result from edema and inflammation (e.g., from active peptic ulceration), while chronic obstruction develops from fibrosis and stricture formation. Edematous benign strictures may partially resolve with medical therapy; established fibrotic strictures require mechanical or surgical intervention.
  • Complications:
  • Prognosis: With appropriate medical and/or endoscopic management, most benign cases resolve favorably. Among patients with peptic ulcer-related GOO, approximately 70–80% respond well to endoscopic balloon dilation combined with H. pylori eradication and acid suppression.[13] Surgical intervention is successful in greater than 90% of cases with benign obstruction when performed by experienced surgeons.

Malignant GOO

  • Natural History: Malignant GOO often represents advanced or metastatic disease. Pancreatic cancer and advanced gastric cancer frequently present with GOO, indicating poor overall prognosis.
  • Complications: Similar to benign cases, including malnutrition, dehydration, and metabolic derangements. Additionally:
  • Prognosis: Prognosis is predominantly determined by the underlying malignancy and its stage. Palliation of obstruction improves oral intake and quality of life but does not alter overall oncologic prognosis. Contemporary series of EUS-GE for malignant GOO report technical success rates of 92–97% and clinical success rates of 85–92%.[14]

Diagnosis

History and Risk Factors

The following clinical history elements are relevant in patients with suspected GOO:[15]

  • History of peptic ulcer disease or its complications (perforation, hemorrhage)
  • History of caustic ingestion
  • Prior gastric or duodenal surgery
  • History of pancreatitis
  • History of malignancy, particularly pancreatic, gastric, or biliary
  • H. pylori status
  • NSAID or anticoagulant use
  • Duration of symptoms (acute vs. chronic onset)
  • Associated systemic symptoms (fever, weight loss, jaundice)

Clinical Presentation

The clinical presentation of GOO is characterized by both early-stage and late-stage symptoms.

Early-Stage Symptoms:

Late-Stage Symptoms:

The timing of symptom onset relative to meals and the composition of vomitus help differentiate GOO from other upper GI disorders. Non-bilious vomitus containing food particles hours after eating is characteristic of GOO.

Physical Examination

Physical examination findings in GOO include:

Laboratory Findings

Laboratory investigations in suspected GOO typically reveal:

  • Acid-Base Disturbance:
    • Metabolic alkalosis — characteristic finding (pH >7.45, HCO3- >26 mEq/L)
    • Results from loss of HCl in gastric secretions
  • Renal Function:
    • Possible prerenal azotemia from volume depletion
    • BUN:creatinine ratio typically >20:1 in dehydration

Imaging Findings

Radiography

  • Plain Abdominal Radiographs (obstruction series):
    • Gastric dilatation (horizontal diameter >3 cm)
    • Air-fluid level (visible on upright films)
    • Absence of normal distal gastric or small bowel gas (suggesting obstruction at the pylorus)
    • Pneumatosis or free air (if perforation has occurred)

Barium Upper Gastrointestinal Study

  • Shows narrowing of the pylorus and/or duodenum
  • Demonstrates delay in gastric emptying of barium
  • Differentiates GOO from gastroparesis (where gastric dilatation exists without pyloric narrowing)
  • Reveals mucosal detail and ulceration
  • Can visualize narrowed segment or mass lesions
  • Less commonly used since advent of CT and endoscopy; limited by aspiration risk

Computed Tomography (CT) with Oral and Intravenous Contrast

CT is the imaging modality of choice for initial evaluation of GOO:

  • Findings suggestive of GOO:
    • Gastric wall thickening (>5 mm) at the pyloric region
    • Pyloric stenosis or narrowing
    • Gastric dilatation (diameter >3 cm)
    • Transition point from dilated proximal stomach to normal-caliber distal duodenum
  • Assessment of Metastatic Disease: CT simultaneously evaluates for distant metastases, lymph node involvement, and peritoneal disease.

Endoscopic Ultrasound (EUS)

EUS has an increasing role in the evaluation and management of GOO:

  • High-resolution imaging of the gastric wall and pylorus
  • Evaluation for malignancy with fine-needle aspiration capability
  • Assessment of pancreatic pathology and tissue sampling
  • Determination of tumor depth (T-staging) in gastric cancer
  • Identification of vascular invasion
  • Guidance for EUS-GE when intervention is planned

Clinical Maneuvers and Functional Tests

Nuclear Medicine Gastric Emptying Study

  • Radioisotope (typically Tc-99m) is administered orally and gastric retention measured at 1, 2, 3, and 4 hours
  • Retention >90% at 2 hours or >10% at 4 hours is abnormal
  • Helps differentiate between mechanical obstruction and gastroparesis (delayed transit without structural obstruction)
  • Confirms diagnosis when imaging is equivocal

Gastric Outlet Obstruction Scoring System (GOOSS)

The GOOSS is a validated four-point scale used to quantify severity of obstruction and monitor response to treatment. It is widely used as a primary outcome measure in interventional trials:[3]

Score Description
0 No oral intake
1 Liquids only
2 Soft solids
3 Low-residue or soft diet
4 Full regular diet

Saline Load Test

  • 750 mL of 0.9% sodium chloride solution is administered via nasogastric tube
  • Gastric contents are aspirated after 30 minutes
  • Retention of >400 mL is diagnostic of GOO
  • Bedside test with limited sensitivity; rarely used in modern practice given availability of imaging and endoscopy

Endoscopy

Upper endoscopy (EGD) is the primary diagnostic and therapeutic procedure in GOO:

  • Diagnostic Benefits:
    • Direct visualization of the gastric outlet and pylorus
    • Assessment of mucosa for inflammation, ulceration, or malignancy
    • Ability to identify the site and approximate extent of obstruction
    • Tissue sampling via endoscopic biopsy — mandatory when malignancy is suspected
    • Exclusion of proximal causes (esophageal or gastric body pathology)
  • Findings in Benign GOO:
    • Narrowed pyloric channel; may see scarring or stricture
    • Peptic ulcer visible at prepylorus or duodenal bulb
    • Polyps (may require endoscopic removal if obstructing)
    • Normal or mildly inflamed mucosa if obstruction is from edema (acute phase)
  • Findings in Malignant GOO:
    • Gastric or duodenal mass with ulceration
    • Narrowed pyloric or duodenal channel with abnormal mucosa
    • Biopsy required for definitive diagnosis
    • May reveal primary tumor (gastric, duodenal, ampullary) or extrinsic compression
  • Technical Considerations:
    • Standard endoscope may not traverse tight stenosis; pediatric or small-caliber endoscope may be needed
    • Care must be taken to avoid perforation when instrumenting through strictured areas

Treatment

Initial Management

All patients with GOO require supportive care as the foundation of management. A key diagnostic principle is to exclude functional causes (gastroparesis) before proceeding with invasive mechanical therapy.

  • Nasogastric Tube Decompression:
    • Placed to relieve symptoms and prevent aspiration
    • Allows assessment of residual gastric volume
    • Facilitates correction of metabolic abnormalities
    • May provide symptomatic relief even in malignant cases
  • Avoid Prokinetic Agents: Do not administer metoclopramide or other prokinetics empirically if mechanical obstruction has not been excluded; prokinetic therapy is contraindicated in true mechanical GOO.

Medical Therapy

Medical management varies by underlying etiology:

Benign Gastric Outlet Obstruction

Malignant Gastric Outlet Obstruction

  • Malignant GOO requires interventional management; medical therapy alone is insufficient for obstruction relief
  • Disease-directed systemic therapy (chemotherapy, targeted therapy) should be administered in parallel with palliative procedural intervention where oncologically appropriate

Procedural/Surgical Therapy

Endoscopic Management

Endoscopic Balloon Dilation (EBD) — Benign GOO
  • Indicated for peptic ulcer disease-related, post-surgical, or other benign strictures
  • Through-the-scope (TTS) or over-the-wire balloon catheters inflated under endoscopic and/or fluoroscopic guidance
  • Balloon diameters typically 15–20 mm; dilated over 60–90 seconds
  • Repeat dilations may be necessary (average 2–4 procedures); not a single-session intervention
  • Success rates: approximately 70–80% long-term success in peptic ulcer-related GOO; caustic-induced GOO requires more sessions (mean 5–8) with lower long-term success (approximately one-third achieve durable results)[3]
  • H. pylori eradication prior to or concurrent with EBD is essential in peptic GOO to improve long-term outcomes[13]
  • Complications: perforation (<5%), bleeding, transient worsening of symptoms
  • Adjunctive intralesional steroid injection may improve outcomes in selected cases
Self-Expandable Metal Stents (SEMS) — Malignant GOO

Uncovered or covered enteral SEMS can be placed endoscopically (with or without fluoroscopic guidance) to relieve malignant obstruction:

  • Per the 2021 ASGE guideline, SEMS placement is preferred over surgical gastrojejunostomy for palliation of malignant GOO in patients with poor prognosis or limited life expectancy, given comparable short-term clinical success, shorter time to oral intake, shorter hospitalization, and lower procedure-related morbidity compared to surgery[3]
  • Uncovered SEMS: Lower migration rates but higher risk of tumor ingrowth; the 2021 ASGE guideline conditionally suggests uncovered SEMS over covered SEMS for malignant GOO based on lower migration risk, acknowledging low certainty of evidence[3]
  • Covered SEMS: Reduced tumor ingrowth but higher migration rates
  • Clinical success: 80–90% short-term symptom relief
  • Stent dysfunction (occlusion or migration) occurs in 10–30% at variable intervals and may require endoscopic re-intervention
  • SEMS remains a valuable, widely available, and less expensive alternative to EUS-GE; however, it carries a significantly higher need for reintervention than EUS-GE in comparative data[16]
EUS-Guided Gastroenterostomy (EUS-GE) with Lumen-Apposing Metal Stents (LAMS)

EUS-GE creates a gastroenteric anastomosis between the stomach and the small bowel distal to the obstruction using a LAMS, effectively bypassing the obstructed segment endoscopically. This approach combines the minimally invasive nature of endoscopy with the durability of a surgical bypass.

Techniques:

  • Free-hand (direct) puncture technique: Antiperistaltic agents and saline irrigation are used; the endoscopist punctures a bowel loop directly under EUS guidance
  • EPASS (double-balloon-occluder) technique: A double-balloon occluder occludes a loop of proximal small bowel near the stomach to facilitate accurate LAMS placement. Both techniques aim to place a lumen-apposing stent between the stomach and distal duodenum or proximal jejunum, with comparable reported outcomes

Evidence Base:

  • A 2025 systematic review and meta-analysis (5 studies, 507 patients: 253 EUS-GE, 254 enteral stenting) demonstrated statistically significant differences favoring EUS-GE over enteral stenting in clinical success, symptom recurrence, and need for reintervention[17]
  • The ENDURO RCT (multicentre, open-label, parallel-group; Netherlands, 2025) randomized 96 patients with malignant GOO to EUS-GE versus surgical gastrojejunostomy. EUS-GE was superior to surgical GE for time to resumption of solid oral intake (median 1 day vs 3 days) and was non-inferior for the rate of persistent or recurrent obstructive symptoms requiring reintervention (10% vs 12%); the authors concluded that EUS-GE should be the preferred palliative treatment for malignant GOO[2]
  • A multicenter retrospective study of 137 patients undergoing EUS-GE for malignant GOO reported technical success in 92.70% (127/137) and clinical success in 88.00%; 42.86% of patients tolerated a regular diet; peritoneal carcinomatosis was associated with lower odds of technical success (OR 0.19, 95% CI 0.04–0.93)[14]
  • EUS-GE also shows durable long-term outcomes in benign GOO; a multicenter retrospective Spanish cohort of 62 patients with benign GOO undergoing EUS-GE (75.8% male, median age 65 years; predominantly pancreatitis-related) demonstrated technical success in 61 (98.4%), immediate clinical success in 57 (91.9%), and oral feeding maintained at 24 months in 85.3% of all patients[18]

Contraindications:

  • Significant uncontrolled ascites
  • Extensive peritoneal carcinomatosis
  • Diffuse malignant infiltration of the gastric or jejunal walls preventing adequate LAMS apposition
Endoscopic Pylorotomy (G-POEM / Per-Oral Pyloromyotomy)
  • Gastric per-oral endoscopic myotomy (G-POEM), also known as per-oral pyloromyotomy (POP), involves submucosal tunneling and division of the pyloric sphincter muscle under endoscopic guidance
  • Primarily utilized for refractory gastroparesis (functional GOO) rather than mechanical obstruction; technical success approaches 100%; short-term (within 1 year) clinical success is approximately 50–80%[19]
  • Procedure time typically 50–70 minutes; average hospital stay 2–3 days
  • Adverse event rate approximately 10%; few patients require further intervention
  • Long-term follow-up studies (4-year data) show durable response, though a yearly recurrence rate of 13% or more has been reported[19]
  • Role in structural (mechanical) GOO is limited; primarily reserved for functional pyloric dysfunction

Comparison of Treatment Modalities

Modality Primary Indication Clinical Success (Symptom Relief) Morbidity Typical Hospital Stay Reintervention Rate
Medical therapy (PPI ± H. pylori eradication) Benign (acute PUD-related) 50–70% Minimal Outpatient Variable
Endoscopic balloon dilation Benign GOO 70–80% (peptic); ~33% (caustic) Low (<5% perforation) 1 day 30–50% need repeat
Enteral SEMS Malignant GOO (limited prognosis) 80–90% Moderate (5–15%) 2–3 days 10–30%
EUS-GE with LAMS Malignant or refractory benign GOO 85–97% (technical 92–98%) Low-moderate (maldeployment ~5%) 1–2 days 10–12% (ENDURO RCT)
Endoscopic pylorotomy (G-POEM/POP) Refractory gastroparesis (functional GOO) 50–80% (short-term) ~10% 2–3 days ~13%/year long-term
Surgical gastrojejunostomy (open) Benign or malignant (good PS, longer life expectancy) 80–90% Moderate-high (10–20%) 5–7 days 5–15%
Laparoscopic gastrojejunostomy Benign or malignant (selected) 80–90% Low-moderate (5–10%) 3–4 days 5–15%

Surgical Management

  • Indications for Surgery:
    • Failure of medical/endoscopic therapy
    • Inability or unwillingness to undergo endoscopic management
    • Penetrating peptic ulcer with perforation
    • Pyloric stenosis (adults with fibrotic obstruction)
    • Certain benign conditions unresponsive to medical/endoscopic therapy
    • Resectable malignancy in fit patients
    • Patient preference
  • Surgical Procedures for Malignant GOO:
    • Gastrojejunostomy (bypass procedure):
      • Palliative bypass of the obstructing lesion
      • Appropriate for unresectable malignancy in patients with adequate performance status and expected survival ≥6 months
      • Success rate: 80–90% for symptom relief
      • Complications: Anastomotic leak, bleeding, dumping syndrome
      • Per the ENDURO RCT, EUS-GE is now preferred over surgical GE for time to oral intake; surgical GE remains appropriate where endoscopic expertise is unavailable[2]
    • Distal gastrectomy or partial gastrectomy:
      • For resectable gastric or distal duodenal cancers
      • May require en bloc resection of invaded organs
      • Offers potential for cure in early-stage disease
    • Whipple procedure (pancreaticoduodenectomy):
      • For resectable pancreatic cancer with GOO
      • Complex surgery with significant perioperative morbidity/mortality
      • Reserved for fit patients with potentially curative intent
    • Prophylactic gastrojejunostomy: May be considered at time of surgical exploration for unresectable periampullary cancer; one RCT demonstrated 0% subsequent GOO in the prophylactic group with no significant increase in morbidity[12]

Long-Term Management

  • Post-Surgical Follow-up:
  • Post-Stent Management (malignant GOO):
    • Clinical follow-up at 1–2 weeks, then as clinically indicated
    • Advance diet gradually as tolerated
    • Monitor for recurrent obstruction, stent migration, or perforation
    • Nutritional support optimization
    • Palliative symptom management; early palliative care consultation
  • Post-EUS-GE Management (benign or malignant GOO):
    • Periodic clinical follow-up; LAMS dysfunction develops in approximately 12% of patients with benign GOO at a median of approximately 1200 days in long-term series; reintervention may be required[18]
    • For malignant GOO, disease-directed oncologic therapy should be co-managed
  • Benign Obstruction (Medical or Endoscopic Management):
    • Regular clinical follow-up
    • Dietary modifications (small, frequent meals; avoid high-fiber or fatty foods)
    • Monitor for recurrent symptoms
    • Compliance with H. pylori eradication and/or PPI therapy in PUD-related cases
    • Repeat endoscopy or imaging only if symptoms recur
  • Nutritional Rehabilitation:
    • Dietitian referral for optimizing oral intake
    • Supplemental nutritional supplements (protein, vitamins, minerals) as indicated
    • Monitoring of body weight and muscle mass

Special Populations

Pediatric Patients (Hypertrophic Pyloric Stenosis)

Hypertrophic pyloric stenosis in infants is managed with Ramstedt pyloromyotomy (open or laparoscopic), which is curative. Medical therapy with atropine is an alternative in selected cases. Metabolic alkalosis must be corrected with intravenous saline and potassium supplementation before anesthesia and surgery.

Acute Peptic Ulcer Perforation with GOO

  • Requires urgent surgical intervention; perforation takes precedence
  • After primary repair or resection of perforated ulcer, address the obstruction if present
  • Vagotomy was traditionally performed but rarely needed given PPI efficacy

Caustic Ingestion

  • Early endoscopy (within 24 hours) to grade severity of injury; endoscopy is contraindicated if there is suspicion of perforation
  • Medical management with NPO status, fluid resuscitation, monitoring for perforation
  • Avoid nasogastric tube in first 24 hours if severe proximal injury
  • Corticosteroid use controversial; may help prevent fibrosis and stricture formation in selected cases
  • Repeat endoscopy at 2–3 weeks to assess for stricture development
  • Early dilation or stent placement may prevent or mitigate stricture formation
  • Delayed surgical intervention if stricture develops despite conservative measures
  • Manage acute pancreatitis medically (NPO, hydration, analgesia)
  • Address underlying cause (gallstone, alcohol)
  • Monitor for pseudocyst development
  • Endoscopic or percutaneous pseudocyst drainage if causing obstruction
  • Surgery rarely needed acutely unless perforation occurs
  • EUS-GE is an emerging option for pancreatitis-related benign GOO refractory to balloon dilation, with favorable short- and long-term outcomes in retrospective series[18]

Bouveret Syndrome

  • Attempt endoscopic mechanical fragmentation and extraction of the gallstone
  • Endoscopic success rates: 50–60%
  • Lithotripsy (extracorporeal shock wave or laser) may fragment large stones
  • Surgery required if endoscopic management fails
  • Cholecystectomy and fistula repair should be performed if stone successfully removed endoscopically

Crohn Disease

  • First-line: Aminosalicylates, corticosteroids, immunosuppressants, TNF-alpha inhibitors
  • Most strictures related to active inflammation resolve with medical management
  • Endoscopic dilation may be attempted for selected fibrostenotic strictures
  • Surgery reserved for medically refractory disease or complications (perforation, fistula, abscess)

Patients with Advanced Malignancy, Poor Performance Status, or Peritoneal Carcinomatosis

  • EUS-GE is relatively contraindicated in extensive peritoneal carcinomatosis; enteral SEMS placement or palliative supportive care should be prioritized
  • Supportive care with NGT and nutrition as primary approach in terminal illness
  • Early palliative care consultation for symptom management and goals-of-care discussions
  • Emphasis on quality of life rather than aggressive intervention

Patients with Malignant GOO and Concurrent Biliary Obstruction

  • Concurrent biliary and GOO occurs frequently in pancreatic and periampullary cancer
  • Combined endoscopic management with biliary drainage (EUS-guided biliary drainage or ERCP with biliary SEMS) and EUS-GE or enteral SEMS may be performed in selected centers with appropriate expertise
  • Multidisciplinary oncologic planning is essential

References

  1. ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 Gan SI, Saltzman JR (2025). "Gastric outlet obstruction in adults: etiology and clinical manifestations". UpToDate.
  2. ↑ 2.0 2.1 2.2 2.3 Kastelijn JB, van de Pavert YL, Besselink MG, Fockens P, Voermans RP, van Wanrooij RL, de Wijkerslooth TR, Curvers WL, de Hingh IH, Bruno MJ, Groot Koerkamp B, Patijn GA, Poen AC, van Hooft JE, Inderson A, Mieog J, Poley JW, Bijlsma A, Lips DJ, Venneman NG, Verdonk RC, van Dullemen HM, Hoogwater FJ, Frederix GW, Molenaar IQ, Welsing PM, Moons LM, van Santvoort HC, Vleggaar FP (2025). "Endoscopic versus surgical gastroenterostomy for palliation of malignant gastric outlet obstruction (ENDURO): a randomised controlled trial". Lancet Gastroenterol Hepatol. doi:10.1016/S2468-1253(25)00209-2. Vancouver style error: initials (help)
  3. ↑ 3.0 3.1 3.2 3.3 3.4 3.5 Jue TL, Storm AC, Naveed M, Fishman DS, Qumseya BJ, McRee AJ, Truty MJ, Khashab MA, Agrawal D, Al-Haddad M, Amateau SK, Buxbaum JL, Calderwood AH, DeWitt J, DiMaio CJ, Fujii-Lau LL, Gurudu SR, Jamil LH, Kwon RS, Law JK, Lee JK, Pawa S, Sawhney MS, Thosani NC, Yang J, Wani SB (2021). "ASGE guideline on the role of endoscopy in the management of benign and malignant gastroduodenal obstruction". Gastrointest Endosc. 93 (2): 309–322.e4. doi:10.1016/j.gie.2020.07.063. PMID 33168194 Check |pmid= value (help).
  4. ↑ Gürkan ÖE, Öztürk H, Kaya C, Kaya NG, Bozbulut NE, Can A, Ceylan K, Aksu AÜ, Düztaş DT, Sarı S (2024). "A Classification for Gastric Outlet Obstruction in Childhood: Extending Beyond Infantile Hypertrophic Pyloric Stenosis". Turk J Gastroenterol. 35 (3): 255–261. doi:10.5152/tjg.2024.23501. PMID 38438029 Check |pmid= value (help).
  5. ↑ Zargar SA, Kochhar R, Nagi B, Mehta S, Mehta SK (1992). "Ingestion of strong corrosive alkalis: spectrum of injury to upper gastrointestinal tract and natural history". Am J Gastroenterol. 87 (3): 337–41. PMID 1539568.
  6. ↑ Poley JW, Steyerberg EW, Kuipers EJ, Dees J, Hartmans R, Tilanus HW, Siersema PD (2004). "Ingestion of acid and alkaline agents: outcome and prognostic value of early upper endoscopy". Gastrointest Endosc. 60 (3): 372–7. PMID 15332026.
  7. ↑ Cappell MS, Davis M (2006). "Characterization of Bouveret's syndrome: a comprehensive review of 128 cases". Am J Gastroenterol. 101 (9): 2139–46. doi:10.1111/j.1572-0241.2006.00645.x. PMID 16817848.
  8. ↑ Kreel L, Ellis H (1965). "Pyloric stenosis in adults: A clinical and radiological study of 100 consecutive patients". Gut. 6 (3): 253–61. PMC 1552275. PMID 18668780.
  9. ↑ Urayama S, Kozarek R, Ball T, Brandabur J, Traverso L, Ryan J, Wechter D (1995). "Presentation and treatment of annular pancreas in an adult population". Am J Gastroenterol. 90 (6): 995–9. PMID 7771437.
  10. ↑ Roy PK, Venzon DJ, Shojamanesh H, Abou-Saif A, Peghini P, Doppman JL, Gibril F, Jensen RT (2000). "Zollinger-Ellison syndrome. Clinical presentation in 261 patients". Medicine (Baltimore). 79 (6): 379–411. PMID 11144036.
  11. ↑ Al-Bawardy B, Rajan E, Wong Kee Song LM (2019). "Gastric outlet obstruction: a red flag, potentially manageable". Cleve Clin J Med. 86 (5): 345–353. doi:10.3949/ccjm.86a.18035. PMID 30762493.
  12. ↑ 12.0 12.1 Lillemoe KD, Cameron JL, Hardacre JM, Sohn TA, Sauter PK, Coleman J, Pitt HA, Yeo CJ (1999). "Is prophylactic gastrojejunostomy indicated for unresectable periampullary cancer? A prospective randomized trial". Ann Surg. 230 (3): 322–8. doi:10.1097/00000658-199909000-00005. PMID 9583691.
  13. ↑ 13.0 13.1 13.2 Lam YH, Lau JY, Fung TM, Ng EK, Wong SK, Sung JJ, Chung SS (2004). "Endoscopic balloon dilation for benign gastric outlet obstruction with or without Helicobacter pylori infection". Gastrointest Endosc. 60 (2): 229–233. doi:10.1016/s0016-5107(04)01569-x. PMID 15278050.
  14. ↑ 14.0 14.1 Vanella G, Bronswijk M, Goudra B, Pérez-Miranda M, Binda C, Larghi A, Dhir V, Martínez B, Kahaleh M, Facciorusso A, Lakhtakia S, Artifon E, Mangiavillano B, Galeotti G, Anderloni A, Fugazza A, Lisotti A, Colombo M, Giuffrida P, Palazzo M, Giannetti A, Tarantino I, Del Chiaro M (2025). "EUS-guided gastroenterostomy for malignant gastric outlet obstruction: impact of clinical and demographic factors on outcomes". Gastrointest Endosc. 101 (2): 287–296. doi:10.1016/j.gie.2024.10.017. PMID 39491733 Check |pmid= value (help).
  15. ↑ Chowdhury A, Dhali GK, Banerjee PK (1996). "Etiology of gastric outlet obstruction". Am J Gastroenterol. 91 (8): 1679. PMID 8759707.
  16. ↑ Miller C, Benchaya JA, Martel M, Barkun A, Wyse JM, Ferri L, Chen YI (2023). "EUS-GE vs. surgical gastrojejunostomy and enteral stenting for malignant gastric outlet obstruction: a meta-analysis". Endosc Int Open. 11 (7): E660–E672. doi:10.1055/a-2098-2570. PMID 37593104 Check |pmid= value (help).
  17. ↑ Asghar M, Forcione D, Puli SR (2024). "Endoscopic ultrasound-guided gastroenterostomy versus enteral stenting for gastric outlet obstruction: a systematic review and meta-analysis". Therap Adv Gastroenterol. 17: 17562848241248219. doi:10.1177/17562848241248219. PMID 38867809 Check |pmid= value (help).
  18. ↑ 18.0 18.1 18.2 Vanella G, López Dóriga P, Pérez-Miranda M, Alonso-Lárraga JO, Muñoz-Garrido V, de la Serna Higuera C, Marcos Pinto R, Repiso Ortega A, Rubio Gil S, Expósito Palomeque A, Martínez Alcalá F, González Haba Ruiz M, de Hierro AL, García Fernández S, Guardiola Arévalo A, Brullet E, Sánchez Carretero MJ, Mínguez Rosique R, Martínez Molina E, Loscos A, Fernández Rueda JL, Oria I, Fernandez Urien I, de la Peña García J, Iglesias García J, Domínguez Muñoz JE, Aparicio JR, Facciorusso A, Libânio D, Dinis-Ribeiro M, Del Chiaro M, Vanbiervliet G, Larghi A (2025). "Long-Term Clinical Success of Endoscopic Ultrasound-Guided Gastroenterostomy in Benign Gastric Outlet Obstruction". Gastrointest Endosc. doi:10.1016/j.gie.2025.06.038. PMID 40671435 Check |pmid= value (help).
  19. ↑ 19.0 19.1 McCurdy GA, Gooden T, Weis F, Mubashir M, Rashid S, Raza SM, Morris J, Cai Q (2023). "Gastric peroral endoscopic pyloromyotomy (G-POEM) in patients with refractory gastroparesis: a review". Therap Adv Gastroenterol. 16: 17562848231151289. doi:10.1177/17562848231151289. PMID 36823490 Check |pmid= value (help).


Template:WikiDoc Sources

Retrieved from "https://www.wikidoc.org/index.php?title=Gastric_outlet_obstruction&oldid=1744813"